Scalper1 News
Medical-device maker Boston Scientific (BSX) beat analysts’ Q3 estimates and raised guidance Wednesday, sending the stock up sharply. Boston Scientific made 24 cents a share in the quarter, excluding one-time items, up 20% from the year-earlier quarter and beating analysts’ consensus by a penny, according to Thomson Reuters. Revenue rose 2% to $1.89 billion, some $27 million above Wall Street’s estimate. Excluding the foreign-exchange impact, Scalper1 News
Scalper1 News